PROJECT SUMMARY The Cancer Clinical Investigator Team Leadership Award (CCITLA) recognizes and supports outstanding clinical investigators who enable their cancer center’s NCI-funded clinical trials enterprise. It is the intent of the CCITLA to support mid-level clinical investigators at NCI-designated Cancer Centers who actively enroll patients and participate extensively and collaboratively in NCI-funded clinical trials. This award is intended to recognize, and support efforts related to interventional trials. The CCITLA is designed to promote the retention of investigators in academic clinical research careers by providing salary support to individuals who do not have independent research grant funding as a Principal Investigator. A candidate for the CCITLA must be nominated by the Cancer Center Director. An ideal candidate will have played a critical role in the development of NCI-funded clinical trials at the cancer center and have a record of service on institutional clinical trial committees and in NCI clinical trial-related activities. Dr. Daniel Catenacci is being nominated for the Cancer Clinical Investigator Team Leadership Award (CCITLA) based on his significant prior experience in NCI-sponsored clinical trials, his ongoing leadership within the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) and his career plans detailed herein to expand patient access and accrual on NCI clinical trials as well as develop a precision-oncology education program within the UCCCC. Funding support provided by this award will facilitate the implementation of two main projects: 1) Building out NCI clinical trial capacity at University of Chicago Medicine Comprehensive Cancer Center (UCCCC) network affiliate sites; and 2) Developing a precision-oncology education program within the UCCCC for fellows in medical oncology, as well as other disciplines in which precision- and immuno-oncology-related medical issues are of relevance.